Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics
Version of Record online: 29 JUL 2006
British Journal of Dermatology
Volume 132, Issue 1, pages 98–105, January 1995
How to Cite
NEJJAM, F., ZAGULA, M., CABIAC, M.D., GUESSOUS, N., HUMBERT, H. and LAKHDAR, H. (1995), Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. British Journal of Dermatology, 132: 98–105. doi: 10.1111/j.1365-2133.1995.tb08632.x
- Issue online: 29 JUL 2006
- Version of Record online: 29 JUL 2006
- Accepted for publication 14 April 1994
In an open pilot study, 12 children with tinea capitis were treated for 6 weeks with oral terbinafine (125mg/day), and followed up 2 weeks later. The study was conducted to evaluate the efficacy, safety and pharmacokinetics of terbinafine.
All patients were completely cured at the end of the treatment period, and there was no evidence of relapse at follow-up. Seven had a negative culture after 3 weeks of treatment. The time to obtain culture conversion from positive to negative did not appear to be related to body weight, but to clinical severity at baseline. Terbinafine is well tolerated and safe over a 56-day period. The kinetic data show a higher clearance of terbinafine in children compared with adults, with shorter α- and β-phase elimination half-lives. However, a longer terminal 7-phase (at least 6 days) is observed, as in adults, after multiple dose administration, and this is related to elimination from the tissues. The plasma concentrations are comparable between children and adults at a steady state (125 mg/day).